Skip to content

News

The Institute generates news every day. Some findings are groundbreaking—some represent smaller steps. But ultimately, it is the combination of both that makes scientific advancement possible. Here is a little selection of the latest stories making it out to the wider world.

Filter by:

Keyword

Showing

German Research Foundation DFG Extends Funding to Support Innovative T Cell Mitochondrial Research

21.01.2026

The Reinhart Koselleck project led by Prof. Luca Gattinoni and Dr. Jeremy Baldwin at the Leibniz Institute for Immunotherapy has received a highly positive interim report evaluation and has been awarded an additional €750,000 in funding to continue their pioneering research into the dynamic role of mitochondria in T-cell biology for the next two years. The decision reflects the exceptional scientific impact of the first funding phase and clears the way for the next stage of this ambitious research program.

Prof. Philipp Beckhove joins CDU “Netzwerk Wissenschaft”

13.01.2026

“Netzwerk Wissenschaft“, a new platform for developing ideas and putting them into practice, has been established by CDU Secretary General Dr. Carsten Linnemann and Prof. Dr. Hendrik Streeck, both Members of the German Bundestag. Prof. Philipp Beckhove, Scientific Director of the LIT, was invited to join the network and contribute his expertise.

LIT Researcher Awarded Prestigious Marie Skłodowska-Curie European Research Fellowship to Cambridge University

05.01.2026

The Marie Skłodowska-Curie Actions (MSCA) is the European Commission’s flagship program designed to support early-career researcher development and foster scientific excellence. Dr. Jeremy Baldwin’s research lies at the crossroads of immunology, synthetic biology and cancer research. During the upcoming fellowship, he will focus on engineering mitochondria for immunotherapy applications. His MSCA research proposal received a perfect score of 100.00% by EC evaluators – an exceptionally rare score achieved by less than 1% of the over 10,500 total MSCA applications.

Extension of SATURN3 Funding for Intratumoral Heterogeneity Research

16.12.2025

Since 2022, scientists at the LIT, led by Prof. Philipp Beckhove, Scientific Director and Head of Interventional Immunology Division, have been investigating intratumoral heterogeneity – the phenomenon that tumors undergo significant individual changes as the disease progresses – as part of the SATURN3 consortium. The Federal Ministry of Research, Technology and Space has extended this funding until June 2027 and increased it by around €220,000 to a total of nearly €600,000.

Podcast “Wirkstoffradio”: Interview with Dr. Markus Barden

15.12.2025

Dr. Markus Barden conducts research at the Leibniz Institute for Immunotherapy (LIT) in the Genetic-Immunotherapy Division, focusing in particular on how CAR T cells can recognize their target structures even more precisely. In the podcast “Wirkstoffradio”, he explains what a CAR T cell is, how T cells identify target structures, and what reactions follow.

How the LIT is developing tomorrow’s immunotherapies from Nobel Prize topics – Interview with Prof. Dr. Philipp Beckhove

12.12.2025

Prof. Dr. Philipp Beckhove, Scientific Director at the LIT, explains in an interview with the Science Blog of the University of Regensburg what influence Sakaguchi’s discovery of “peripheral” immune tolerance, in particular regulatory T cells (Tregs), had on immunology, how the collaboration with Shimon Sakaguchi came about, and how the new findings are paving the way for future immunotherapies.

Alzheimer’s Research Meets Art – Now Online

08.12.2025

The LIT was pleased to host „Alzheimer’s Research Meets Art“ – an Art Exhibition inspired by the Biomedical Research by Prof. Stefan Rüdiger.
For those who were unable to attend in person, we have now published photographs of the exhibited pieces accompanied by explanatory texts on our website.

The LIT participates in the Leibniz Lab Pandemic Preparedness

01.12.2025

How can we better prepare for future pandemics? This question is the focus of the Leibniz Lab Pandemic Preparedness, of which the Leibniz Institute for Immunotherapy (LIT) recently became a member. The LIT will contribute by investigating the molecular mechanisms of secondary diseases resulting from infections, such as ME/CFS or Long COVID syndrome, in greater detail.

Healing the gut after cancer therapy: Immune cells turn damage into repair

27.11.2025

Regulatory T cells (Tregs), a specialized type of immune cells, are usually seen as “peacekeepers” that prevent excessive immune attacks. Surprisingly, a new study published in “Signal Transduction and Targeted Therapy” shows that Tregs utilize inflammatory signals to start repair processes following cancer therapy. The research conducted by the LIT Cooperation Group “Innate Immune Sensing in Cancer and Transplantation” in cooperation with researchers from the Department of Radiation Oncology at the Technical University of Munich (TUM) uncovers how the body`s own immune system can be harnessed to repair the intestinal lining and improve survival.